During Tuesday’s Morning trade, Shares of EVINE Live Inc (NASDAQ:EVLV), lost -12.20% to $2.16.
EVINE Live Inc. (NASDAQ: EVLV)
FY 2015 Third Quarter Highlights
- Net sales were $162.3 million, a 3% improvement year-over-year.
- Online net sales as a percentage of total net sales raised 250 basis points to 46%.
- Mobile remains the fastest-growing platform with net sales of $31.2 million, a 34% improvement year-over-year.
- Active customer count during the quarter raised 3% year-over-year, while reactivated customer count raised 4% year-over-year.
- Average purchase frequency raised to 4.1 units per customer, a 4% improvement.
- Adjusted EBITDA was $0.2 million.
EVINE Live Inc., declared results for the third quarter ended October 31, 2015.
“We are happy with our third quarter results as the sales trends we practiced last quarter have continued,” said Mark Bozek, Chief Executive Officer of EVINE Live. “We enter the holiday season with optimism in our merchandise assortment and growth strategies.”
EVINE Live Inc. operates as a digital commerce company in the United States. The company markets, sells, and distributes products to consumers through TV, online, mobile, and social media in the merchandise categories of home, beauty, health and fitness, fashion and accessories, jewelry and watches, and consumer electronics.
Shares of T-Mobile US Inc (NASDAQ:TMUS), inclined 0.58% to $38.24, during its current trading session.
T-Mobile,is kicking off the holidays in style with Un-carrier Unwrapped, a full month of holiday gift-giving, with one special gift coming each week. First up, the Un-carrier is giving the gift of unlimited high-speed data for your smart phone – for the next three months – to every single one of its postpaid Simple Choice customers. But in true T-Mobile fashion, we won’t stop there. T-Mobile is also delivering special holiday gifts to Sprint, AT&T and Verizon customers starting next week – one carrier per week. Plus, T-Mobile is serving up a banquet of holiday offers, counting a free tablet, $0 down $0 per month on the Samsung Galaxy S6 32GB with JUMP! On Demand, and more.
“We’ve had a fantastic year, and we’re going to spread that T-Mobile cheer by starting with the most important people first… our existing customers! Now you get Unlimited LTE data on our blazing fast network for three full months as a gift from the Un-carrier to you,” said John Legere, president and CEO of T-Mobile. “But that’s not all….we know that Verizon, AT&T and Sprint customers need some holiday cheer, too - so we’ve got presents coming for them. Just wait!”
T-Mobile US, Inc., together with its auxiliaries, provides mobile communications services in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. It also provides wireless devices, such as smart phones, tablets, and other mobile communication devices, in addition to accessories, which are manufactured by various suppliers.
Finally, Shares of Synthetic Biologics Inc (NYSEMKT:SYN), lost -3.53%, and is now trading at $2.73.
Synthetic Biologics, declared that the U.S. Patent and Trademark Office has issued a patent that covers use of a range of compounds, counting the active agent of SYN-010, for the treatment of irritable bowel syndrome with constipation (IBS-C). This is Synthetic Biologics’ first issued U.S. patent directly pertaining to SYN-010 and adds to the Company’s extensive IBS-C patent estate.
U.S. Patent No. 9,192,618, issued on November 24, 2015, comprises claims that cover Synthetic Biologics’ clinical SYN-010 IBS-C program. This patent, which is exclusively licensed from Cedars-Sinai Medical Center (CSMC), is the result of research directed by Mark Pimentel, M.D., FRCP(C), Director of CSMC’s GI Motility Program and Laboratory and Chairman of Synthetic Biologics’ IBS-C Clinical Advisory Board. This new U.S. patent enlarges Synthetic Biologics’ SYN-010-related patent estate; patents from the same family have been granted in Europe, Canada and Australia. Additional worldwide patent filings, co-owned by CSMC and Synthetic Biologics and licensed to the Company, comprise composition of matter claims that could extend patent protection of SYN-010 to 2035.
SYN-010 is Synthetic Biologics’ proprietary, modified-release formulation of lovastatin lactone that is intended to reduce methane production by certain microorganisms (M. smithii) in the gut while minimizing disruption to the microbiome. SYN-010 is intended to act primarily in the intestinal lumen, ideally limiting systemic absorption, thereby targeting a major cause of IBS-C, not just the symptoms. Synthetic Biologics anticipates a 505(b)(2) regulatory pathway for SYN-010.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis.